Woodhead, J
Fujimaki S, Kuwabara T
GLP-1 Receptor Agonists (e.g., semaglutide, liraglutide) Increase insulin secretion in response to food Reduce glucagon release (which lowers blood sugar) Slows gastric emptying (which helps with post-meal glucose excursions) Reduces appetite and induces satiety which leads to weight loss GLP-1/GIP Receptor Agonists (e.g., tirzepatide) GLP-1 effects (same as above) GIP effect: further enhances insulin secretion Both medications help with blood sugar control and weight loss, but Mounjaros dual mechanism may offer stronger effects on insulin secretion, which improves A1c levels
From a public health perspective, the widespread implementation of microbiome-targeted therapies could alleviate the burden of obesity and depression, two prevalent conditions with significant societal and economic costs
December 2025: Emcure Pharmaceuticals launched Poviztra, a semaglutide-based weight-loss therapy, at USD 106 (INR 8,790) per month, becoming the first Indian company to commercialize Novo Nordisks molecule for obesity
THE PRODUCTS DESCRIBED HEREIN ARE FOR LABORATORY AND RESEARCH USE ONLY